Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis by Deepa Lalla et al.
a SpringerOpen Journal
Lalla et al. SpringerPlus 2014, 3:350
http://www.springerplus.com/content/3/1/350RESEARCH Open AccessWillingness to pay to avoid metastatic breast
cancer treatment side effects: results from a
conjoint analysis
Deepa Lalla1, Rashad Carlton2*, Eduardo Santos3, Thomas Bramley2 and Anna D’Souza2Abstract
Purpose: Metastatic breast cancer (MBC) patients are treated with a variety of regimens with differing side effects
that can reduce the patients’ quality of life. This study assessed the willingness to pay (WTP) to avoid side effects
related to MBC treatment using conjoint analysis.
Methods: An online, self-administered conjoint analysis survey of US adult female MBC patients was conducted to
elicit preferences for MBC treatment side effects. Attributes included in the analysis were hair loss, diarrhea, fatigue,
nausea, tingling in hands and feet, pain, risk of infection, and out-of-pocket costs. Fifteen choice-based conjoint
questions were presented where patients selected the most preferred therapy. A partial profile design was used to
allow for each treatment description to be made with 3 instead of all 8 attributes. The attribute choices for each
question included 2 side effects and a yearly out-of-pocket price.
Results: There were 298 respondents. MBC patients were willing to pay (US$) $3,894 to avoid severe diarrhea,
$3,479 to avoid being hospitalized due to infection, $3,211 to avoid severe nausea, $2,764 to avoid severe tingling
in hands and feet, $2,652 to avoid severe fatigue, $1,853 to avoid obvious hair loss, and $1,458 to avoid severe pain.
The most important attributes when selecting a therapy for MBC in terms of average utility were risk of infection,
diarrhea, and nausea.
Conclusions: MBC patients were willing to pay significant amounts to avoid side effects associated with MBC
treatment, with patients willing to pay the most to avoid diarrhea, risk of infection, and nausea.
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Breast cancer is the most frequently diagnosed cancer in
women after skin cancer. It is estimated that 226,870
women will be diagnosed with and 39,150 women will die
of breast cancer in 2012 (Howlader et al. 2012). The over-
all 5-year relative survival for breast cancer from 2002 to
2008 was 89.0%. The majority of women with breast can-
cer will present with the disease localized to the primary
site (60%) or with spread to regional lymph nodes (33%),
where the 5-year relative survival is over 80% (Howlader
et al. 2012). Approximately 5% of women with breast can-
cer present with more severe metastatic disease at diagno-
sis (Howlader et al. 2012). The 5-year survival rate for* Correspondence: rashad.carlton@xcenda.com
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is only 23.8% (Howlader et al. 2012). Newer chemotherapy
agents and hormone agents used for the treatment of
MBC have led to significant improvements in patients’
survival (Pal et al. 2012; Andre et al. 2004; Chia et al.
2007). As survival improves, patients are being exposed to
therapy for longer periods of time, and quality of life
optimization is a goal of treatment. Agents used in the
treatment of MBC may have associated side effects that
can affect and reduce quality of life for patients with MBC
(Romond et al. 1995; Piccart-Gebhart et al. 1995; Shapiro
and Recht 2001; Tannock et al. 1998; Osaba et al. 2003).
These associated side effects, which vary by agent, can be
an important consideration when evaluating the best regi-
men for a patient.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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vere disruptions in quality of life are less willing to receive
additional treatment for an extension of life by 6 months
compared with women who experienced no or little dis-
ruption in normal life (Lindley et al. 1998). Assessing
the perceived value of a lower risk of toxicity provides
additional information on how patients view the toler-
ability of chemotherapy agents, potentially assisting in
the selection of preferred agents. The objective of this
analysis was to assess the importance of MBC treatment
side effects and to assess the willingness to pay (WTP)
to avoid these side effects.
Methods
A survey was developed using conjoint analysis to elicit
preferences or utilities for treatments for MBC based on
the side-effect profile of the treatment. Conjoint analysis
involves comparing hypothetical scenarios by ranking, rat-
ing, or choosing a particular scenario (Phillips et al. 2002).
Conjoint analysis elicits preferences by asking respondents
to evaluate alternatives consisting of different combinations
of attributes (Phillips et al. 2002). Respondent choices indi-
cate the relative importance of the product attributes and
provide data for estimating utilities. The conjoint analysis
technique is based on economic theory and the assump-
tion that individuals maximize a preference (or utility)
function (Phillips et al. 2002). Conjoint analysis can also be
used to estimate how individuals trade between attributes;
for example, the rate at which they are willing to give up
one unit of an attribute for an increase in another attribute
(Ryan 1999). This is known as the marginal rate of substi-
tution (MRS). When applied to the current study, treat-
ments for MBC were defined in terms of their side-effect
profile, with the side effects constituting the attributes of
the treatment. The conjoint analysis technique was then
used to obtain utilities for each of the treatment-related
side effects.Table 1 Attributes and levels of side effects
Attribute
Mild/Low Modera
Hair loss None/not noticeable
Fatigue None/full activity I often need a
Nausea None/easy to ignore Manageable with
Pain None/easy to ignore Manageable w
(eg, Ad
Diarrhea 2 stools or less/day 3+ loose
Risk of infection None/modest
Tingling in hands and feet None/easy to ignore Bothersome
Out-of-pocket cost $500 $
Key: OTC – over-the-counter.The conjoint analysis technique consists of 5 steps
(Ryan and Farrar 2000). First, the attributes are defined.
Seven side effects of MBC treatments were chosen as
attributes for the survey. The side effect attributes were
hair loss, fatigue, nausea, pain, diarrhea, risk of infection,
and tingling in hands and feet. Additionally, cost was
included as an attribute to allow for calculation of the
WTP to avoid side effects. Second, the levels for each of
the attributes are set. Levels for the attributes were
based on severity of mild/low, moderate/medium, or
severe/high (Table 1). Attributes and levels were selected
based on the literature and in collaboration with clini-
cians based on the side effects and severity levels com-
monly seen in clinical practice when treating MBC
patients. Attributes were described in non-medical, lay
terminology so that they could be easily understood by
patients (eg, “hair loss” instead of “alopecia”).
Third, scenarios are created. The 8 attributes in the ana-
lysis, each with 2 or 3 levels, give rise to 2,916 possible
combinations (36 × 22 = 2,916). It is implausible to assess
the utility for each respondent on all attributes and levels
with such a large number of possible combinations. An or-
thogonal main effects design was therefore used to reduce
the number of possible combinations to a manageable
level while still being able to infer utilities for all possible
scenarios (Ryan 1999). The orthogonal design resulted in
the creation of 15 survey versions for each respondent.
Previous research suggests that individuals can manage
between 9 and 16 pairwise comparisons before they
become tired or bored (Pearmain et al. 1991). Addition-
ally, a partial profile design was chosen over a full-profile
design that allowed for treatment descriptions to be made
with 3 instead of all 8 attributes (Ryan and Farrar 2000).
Each treatment choice was described in terms of 2 side
effects (randomly chosen) and an out-of-pocket cost level.
Fourth, preferences are established (Ryan and Farrar
2000). In this analysis, we employed the discrete-choiceLevel of severity
te/Medium Severe/High
– Obvious
nap to reset myself Major impact on my activity level




stools per day Unable to leave the house due to frequency
and urgency of diarrhea
– Hospitalized due to infection
but manageable Interferes with activities of daily living
(eg, getting dressed)
1,000 $3,000
Table 2 Description of study sample
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ment choices for each conjoint question and were asked
to choose their preferred treatment. The discrete choice
approach was preferred as it mimics the manner in which
decisions are made in real life and is based on random
utility theory (Ratcliffe 2000). The final step in the con-
joint analysis process is data analysis (Ryan and Farrar
2000). The random effects multinomial logit model in
Sawtooth software was used to analyze the data. Effects
coding was used to scale the sum to zero within each attri-
bute for determining conjoint utilities/value to the patient
(Orme 2010). The relative importance of the side effects
was obtained by averaging the absolute values of the attri-
bute level coefficients across levels of attributes, including
the baseline coefficients. WTP was estimated as the
amount respondents were willing to pay to avoid each side
effect level and have a baseline level of no or minimal side
effect. This was calculated by dividing the coefficient
differences between the baseline level of no or minimal
side effect and the respective side-effect level by the co-
efficient for out-of-pocket cost (Orme 2010).
The survey was fielded as an online, self-administered
survey to MBC patients. Patients were identified from a
US consumer panel of breast cancer patients and were
sent an email link to complete the survey. Respondents
were compensated (gift certificate, <$25) for their time
for completing the survey. Survey respondents com-
pleted 15 conjoint analysis questions in addition to back-
ground demographic questions and questions on their
history of side effects while on MBC treatments.
Results
There were a total of 298 respondents. The majority of
respondents were white (84%), married (57%), over
40 years old (86%), and had private insurance (57%).
Respondents were evenly distributed across the country
and mostly resided in suburban areas (53%). Most respon-
dents had a degree (associates or higher) and a household
income above $50,000 (53%) (Table 2).
Metastatic breast cancer experience
Approximately 71% of patients were receiving treatment
for MBC at the time of the survey. The most common
chemotherapies mentioned as part of their current regi-
men included paclitaxel, trastuzumab, doxorubicin, ana-
strozole, and cyclophosphamide (Figure 1). The average
Figure 1 Current or most recent treatment regimen. Other chemotherapy treatments reported were letrozole, zoledronate, ixabepilone,
cyclophosphamide, fulvestrant, anastrozole, tamoxifen, exemestane, denosumab, mitomycin, eribulin, leuprolide, pamidronate, lapatinib,
raloxifene, ibandronate.
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last regimen was $832. Most respondents (i) experienced
moderate fatigue; (ii) lost none or only some of their
hair, and (iii) experienced mild to moderate nausea, pain,
diarrhea, and tingling of hands and feet. The impact of
side effects on quality of life was closely related to seve-
rity of adverse events. As respondents experienced more
severe side effects, they reported a more negative quality
of life (Figure 2).
Willingness to pay
Conjoint analysis was used to determine the maximum
yearly total out-of-pocket amount that respondents
would be willing to pay for an entire course of therapy
that would provide equal effectiveness and a reduction
in treatment-related side effects. WTP serves as a proxy
of patient utility by measuring patients’ desire to avoid
side effects that can negatively affect the treatment’s
value to the patient. The side effects that patients were
willing to pay the most to avoid were diarrhea so se-
vere they could not leave the house ($3,894), being
hospitalized due to an infection ($3,479), nausea so
severe that they could not eat ($3,211), and tingling in
the hands and feet that interferes with daily activities
($2,764) (Figure 3).Value to patient
The average value to patients (part-worth utility) for each
attribute was calculated using effects coding. The relative
importance of each attribute was determined based on the
range of each attribute’s utility values. The attributes with
the most utility to patients were risk of infection (1.0090),
diarrhea (0.8809), and nausea (0.7709) (Table 3).
Discussion
The results of the analysis indicate that patients were
willing to pay over $3,000 a year to avoid severe diar-
rhea, being hospitalized due to infection, and severe
nausea. The most important attribute based on utility to
patients in treatment decisions was the risk of infection/
febrile neutropenia. In previous conjoint analysis re-
search in patients with breast cancer, neutropenia with
hospitalization, nausea, and fatigue were found to have
the most impact on patients’ preferences for chemothe-
rapy (Beusterien et al. 2012). The results of this analysis
are consistent with previous patient preference research
using conjoint analysis. Previous research on the health
utilities of MBC side effects has shown that febrile neu-
tropenia/risk of infection has a major impact on quality
of life (utility -0.150) (Lloyd et al. 2006). The utility for
febrile neutropenia was higher than the utility for other
Figure 2 Impact of side effects on quality of life by Severity of Side Effects. (a) Hair loss (b) Fatigue (c) Pain (d) Diarrhea (e) Tingling in
hands and feet.
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(-0.115), hair loss (-0.114), and diarrhea/vomiting (-0.103)
(Lloyd et al. 2006). The utilities of attributes from this ana-
lysis are consistent with previous research on the utilities
of MBC, with febrile neutropenia having the largest
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Figure 3 Average yearly willingness to pay for a reduction in treatmediarrhea had higher utility to patients than in previous
research. This may be driven by the conjoint methodology
and the distribution of levels of diarrhea, with the most
severe level of diarrhea leaving the patient in a state where
they are unable to leave the house due to the frequency











nt-related side effects by Severity of Side Effects.
Table 3 Average value to patient of a reduction in side effects
Attribute Levels Value to patient Average value to
patient
Importance
Hair loss None/not noticeable 0.5374 0.5374 6
Obvious -0.5374
Fatigue None/full activity 0.6941 0.5628 5
I often need a nap to reset myself 0.1501
Major impact on my activity level -0.8841
Nausea None/easy to ignore 0.7060 0.7709 3
Manageable with OTC medication (eg, Advil, Tylenol) 0.0854
Need prescription-strength medication -0.4654
Diarrhea 2 stools or less per day 0.9371 0.8809 2
3+ loose stools per day 0.3842
Unable to leave the house due to frequency and urgency
of diarrhea
-1.3213
Risk of infection None/modest 1.090 1.090 1
Hospitalized due to infection -1.090
Tingling in hands and feet None/easy to ignore 0.6693 0.6624 4
Bothersome, but manageable 0.2643
Interferes with daily activities (eg, getting dressed) -0.9336
The average value to patients is the part-worth utility calculated using effects coding. The relative importance of each attribute was determined based on the
range of each attribute’s utility values.
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lysis are different from those seen when patients are asked
directly which side effect they would most like to avoid. In
a previous survey of 202 MBC patients, the side effects
patients responded that they were most likely to pay extra
to avoid were hair loss (28.2%), pain (16.8%), and nausea
(14.9%) (Lalla et al. 2011). In the previous survey, patients
assessed the importance of each side effect individually
without reference to price or the severity of the side effect
and without any tradeoffs between attributes. When
presented with conjoint questions looking at different
scenarios and faced with tradeoffs between attributes, hair
loss and pain went from 2 of the most important attributes
to the least 2 important attributes in a conjoint analysis.
When presented with an open-ended question to
assess how much they would be willing to pay for a 25%,
50%, or 100% reduction in MBC treatment side effects,
respondents were willing to pay $1,886 for a 25% reduc-
tion in MBC treatment side effects, $3,837 for a 50%
reduction in MBC treatment side effects, and $7,794 for
a 100% reduction in MBC treatment side effects (Lalla
et al. 2011). In the previous survey, patients were willing
to pay more to avoid treatment-related side effects when
presented with an open-ended response. The difference
in the WTP estimates between this study and Lalla et al.
(2011) is likely due to the discrete choice framework
approach used in the current study, where respondents
are effectively locked into the choice between the sce-
narios presented (Ratcliffe 2000). For example, in oursurvey, the lowest out-of-pocket cost was $500. The
respondent may only be willing to pay $300 for the sce-
narios under consideration. The respondent is unable to
give his/her true preference as their WTP amount is not
a given option. Similarly, the highest out-of-pocket cost
in our survey was $3,000. There may be some patients
who are willing to pay more than $3,000 for one of the
scenarios, and thus they are unable to give their true
willingness to pay value.
Limitations
This analysis has a number of limitations. First, these
results do not specifically correlate WTP with insurance
status or other determinants of out-of-pocket costs.
Patients were asked to choose scenarios based on the
yearly out-of-pocket costs; however, patient factors such
as insurance status, socioeconomic background, income
level, and comorbid diseases may affect the willingness
and ability to pay for MBC treatments. Finally, results
from this survey may not be generalizable to the entire
MBC patient population. This survey population repre-
sents a small subset of the MBC patient population who
were healthy enough and willing to complete a 30-minute
online survey.
Conclusions
Patients highly value reductions in side effects associated
with MBC treatment and are willing to pay higher out-
of-pocket costs to avoid the side effects that cause the
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had the most value or utility to respondents were risk of
infection, diarrhea, and nausea. Although risk of infec-
tion was considered by respondents to be the most
important side effect, as measured by the average
utilities, survey respondents had the highest WTP for
avoidance of severe diarrhea. Understanding patients’
perspectives and preferences on which side effects they
most wish to avoid can aid value-based decision making
when selecting between MBC treatment options.
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